Company intelligence / Profile preview
Immatics US, Inc.
Houston, Texas, United Statesimmatics.com ↗
- Ownership
- Private
- Employees
- ~700
- Development stage
- Other
01
Overview
Immatics has advanced a broad PRAME-focused franchise with both T cell receptor engineered T cell therapies (TCR-T) and TCR bispecifics. Its lead program (anzutresgene autoleucel, targeting PRAME) is in Phase 3 for melanoma and has shown strong anti-tumor activity and durability in metastatic melanoma in recent studies. The company is actively enrolling in multiple ongoing clinical trials and has multiple assets in Phase 1 and preclinical stages[1][3][4].
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Bristol Myers SquibbGenmab
Beyond the preview
Go deeper on Immatics US, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immatics US, Inc..